 Polymorphic repeats in human genes |
| OF PARTICULAR EMBODIMENTS OF THE INVENTION The following descriptions of particular embodiments ... |
|
| Semaphorin gene: Semaphorin Y |
| What is claimed is: 1. An isolated nucleic acid molecule comprising a polynucleotide having a ... |
|
| Non-maltogenic exoamylases and their use in retarding retrogradation of starch |
| What is claimed is: 1. A process for making a bakery product comprising: (a) adding to a starch ... |
|
| Attenuated equine herpesvirus |
| The first objective of the present invention is achieved by an Equine herpesvirus (EHV) mutant, ... |
|
| Conserved yeast nucleic acid sequences |
| OF THE INVENTION The present invention advantageously provides both probes and primers which bind ... |
|
| Compositions and methods for the therapy and diagnosis of prostate cancer |
| Briefly stated, the present invention provides compositions and methods for the diagnosis and ... |
|
| Compositions structured with at least one polymer and methods of using the same |
| What is claimed is: 1. A structured cosmetic composition comprising: (i) at least one continuous ... |
|
| Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
| The present invention provides significant improvements in therapeutic uses of BPI protein products ... |
|
| Synthesis of soluble .beta.-sheet forming peptides |
| OF THE INVENTION An intricate interplay exists between peptide .beta.-sheet formation, self-... |
|
|
Method of immunomodulatory treatment of insulin dependent diabetes mellitus using mycobacterial cell wall compositions
| Details |
Inventors: Baxter, Alan George;
Assignee: Centenary Institute of Cancer Medicine and Cell Biology (Camperdown, GB)
Primary Examiner: Devi; S.
Assistant Examiner:
Attorney, Agent or Firm: Morrison & Foerster LLP
The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the effects of insulin-dependant diabetes mellitus (IDDM) by administering a cell wall subunit or a chemical or functional equivalent thereof from Mycobacterium or a related organism or other suitable biological source. The present invention is further directed to a pharmaceutical composition useful in preventing, delaying onset of, curing, curing in association with islet replacement or otherwise ameliorating the effects of autoimmune conditions such as IDDM or for enhancing an immune response against melanoma or other cancer comprising a cell wall subunit or a chemical or functional equivalent thereof from Mycobacterium or a related organism or other suitable biological source. The cell wall subunit is preferably mycolyl-arabinogalactan-peptidoglycan (MAPG) or a component thereof. |
|
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS The present invention contemplates a method of immunomodulatory therapy in a mammal said method comprising administering to said mammal an immunomodulating effective amount of one or more components of the cell wall of Mycobacterium or a related organism or analogous components from another biological source or chemical equivalents of said components.
In one aspect, the present invention is directed to a method of preventing, delaying onset of, curing or otherwise ameliorating the effects of an autoimmune disease in a mammal said method comprising administering to said mammal an autoimmune-preventing effective amount of one or more components of the cell wall of Mycobacterium or a related organism or analogous components from another biological source or chemical equivalents of said components.
In another aspect, the present invention provides a method of enhancing an immune response against melanoma or other cancer in a mammal said method comprising administering to said mammal an immunomodulatory effective amount of one or more components of the cell wall of Mycobacterium or a related organism or analogous components from another biological source or chemical equivalents of said components.
Autoimmune conditions contemplated by the present invention include but are not limited to IDDM, thyroiditis, atrophic gastritis (type A), pernicious anaemia, Addison's disease, pemphigus vulgaris, pemphigoid, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, discoid lupus erythematosus, haemolytic anaemia, sympathetic ophthalmia, uveitis, idiopathic thrombocytopenia, idiopathic leucopenia, primary biliary cirrhosis, autoimmune chronic active hepatitis, ulcerative colitis, Sjogren's syndrome, dermatomyositis, scleroderma and mixed connective tissue disease.
Cancers contemplated for immunomodulatory therapy include but are not limited to bladder cancer, carcinoma, melanoma amongst many others.
The present invention is hereinafter described in relation to IDDM but this is done with the understanding that the invention extends to autoimmune diseases such as contemplated above as well as the immunomodulatory therapy of cancers
|
|
Drugs 
